Welcome to BIG, a newsletter on the politics of monopoly power. If you’d like to sign up to receive issues over email, you can do so here.In 2022, an executive at a health insurance company expressed concern at the games his company was playing with drug prices. He pointed at the drug Gleevec, which when it was approved in 2001, was a miracle treatment for blood cancer. “For a lot of people, Gleevec was simply too good to be true. But these once-dying patients were getting out of bed, dancing, g...